Category Archives: Non classé

Our partner IMéBIO, a company expert in modular technical environments for biotechnology and health, has delivered a mobile and autonomous BSL-3 laboratory of 45 m2 to allow us to amplify our collaborative research activities in the fight against emerging and re-emerging infectious diseases. These additional laboratory spaces will in particular make it possible to accelerate our various R&D programs carried out with our spin-off VirexpR in the field of microbiological contamination of indoo...

Virnext is very proud to have contributed with its partner Cynbiose to preclinical assessment and accelerating transfer to clinical trial of the HIPRA’s Covid-19 BIMERVAX® vaccine, recently approved by the European Medicines Agency. Virnext has been committed for several years in the development of in vitro and in vivo preclinical models of infections dedicated to the screening and evaluation of antiviral, antibody and vaccine candidates against emergent and re-emergent respiratory viruses...

This consortium is part of the partnership dynamic that we initiated in November 2020 with the Auvergne-Rhône-Alpes Region, the Lyonbiopôle competitiveness cluster and the company VirHealth by implementing the first studies in Europe to evaluate in a test chamber the performance of several air treatment devices in an atmosphere contaminated by the infectious SARS-CoV-2 virus. On the basis of the experimental results obtained and previous technical knowledge of these devices, the Auvergne-Rhôn...

VirNext provides expertise in the field of respiratory viruses (influenza, pneumoviruses, adenovirus, rhinovirus, coronaviruses and all SARS-CoV-2 variants of interest) and a large panel of technologies including egg and cell-based process of virus and vaccine antigen production, and several in vitro and in vivo preclinical models of infection. Here under is a reconstructed human airway epithelium MucilAir (Epithelix) infected by the SARS-CoV-2 B.1.617.2 Delta strain observed by confocal micr...

Our technological research platform VirNext is very proud of the spin-off VirexpR which has just reached a major step in its technological and strategic development plan. Thanks to its partner ASPIDA for the joint design and realization of this unique test bench in Europe which will allow VirexpR to position itself as an international reference in the management of microbiological and virological environmental pollution, and indoor air quality in confined spaces, whose health,...

Our results support considering the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection. Our models of SARS-CoV-2 infection in reconstituted Human Airway Epithelium (MucilAir) were predictive again of the results obtained in the cynomolgus NHP model, demonstrating that favipiravir, even at doses up to 600 μM, has no antiviral efficacy against SARS-CoV-2.  Although our results are in contradiction with those obtained in...

Cynbiose and VirNext have joined forces to offer a unique and innovative preclinical package of services for the evaluation of drugs, vaccines and antibodies candidates against (re)-emergent respiratory viruses, from in vitro screening to in vivo efficacy models of infections, including large animals. On the basis of a public-private partnership initiated in 2017, we have contributed to the evaluation of hundreds of candidates for respiratory viruses, including SARSCoV2 variants, cell lines, rec...

VirNext est très fière d'être lauréate du prix de l'innovation 2021 #Contaminexpo remis par Bastien Cany et Stéphane ORTU. Nous remercions l'Aspec Association, Salles Propres et les membres du jury pour leur confiance et la reconnaissance de nos savoir-faire dans la génération d'atmosphères hautement contaminées par des virus respiratoires, incluant le #SARSCOV2, dédiés à l'évaluation des technologies et dispositifs épurateur d'air. Un grand merci à toutes les équipes de l'Asp...

Notre plateforme VirNext était présente du 12 au 15 octobre au salon #Pollutec à Lyon Eurexpo afin d’échanger sur nos savoir-faire uniques dans l’évaluation des technologies de purification de l’air contre le virus SARS-CoV-2 et autres virus respiratoires pathogènes....

Notre plateforme VirNext est toujours mobilisée dans la lutte contre la Covid-19 en évaluant expérimentalement différentes technologies de purification de l’air en partenariat avec Lyonbiopôle #CentreInnovation et dans la dynamique insufflée par la Région Auvergne-Rhône-Alpes. VirNext présentera ses expertises et services pour l’évaluation de performance des technologies de décontamination de l’air intérieur contre les virus respiratoires au salon #ContaminExpo, le rend...